A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Small, Eric Jay
Lance, Raymond S.
Redfern, Charles H.
Millard, Frederick E.
Gardner, Thomas A.
Karsh, Lawrence Ivan
Dawson, Nancy Ann
McCoy, Candice
Stubbs, Andrew
DeVries, Todd
dela Rosa, Corazon P.
Sheikh, Nadeem A.
Shore, Neal D.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[3] Sharp Clin Oncol Res, San Diego, CA USA
[4] Moores UCSD Canc Ctr, San Diego, CA USA
[5] Urol Indiana Univ Hlth, Indianapolis, IN USA
[6] Urol Ctr Colorado, Denver, CO USA
[7] Georgetown Univ Med Ctr, Washington, DC USA
[8] Dendreon Corp, Seattle, WA USA
[9] Carolina Urol Res Ctr, Myrtle Beach, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5047
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC) in the era of enzalutamide (ENZA) and abiraterone acetate (AA).
    Body, Amy
    Pranavan, Gane
    Malik, Laeeq
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
    Chi, K. N.
    De Bono, J. S.
    Higano, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C plus DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
    Al Harthy, Munjid
    Madan, Ravi Amrit
    Karzai, Fatima
    Petrylak, Daniel Peter
    Kim, Joseph W.
    Arlen, Philip M.
    Theoret, Marc Robert
    Marte, Jenn
    Bilusic, Marijo
    Couvillon, Anna
    Chun, Guinevere
    Owens, Helen
    Hankin, Amy
    Cordes, Lisa M.
    Figg, William Douglas
    Gulley, James L.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC)
    Marshall, Catherine Handy
    Park, Jong Chul
    DeWeese, Theodore L.
    King, Serina
    Afful, Michaella
    Hurrelbrink, Julia
    Manogue, Charlotte
    Cotogno, Patrick
    Moldawer, Nancy P.
    Barata, Pedro C.
    Drake, Charles G.
    Posadas, Edwin M.
    Armstrong, Andrew J.
    Sartor, A. Oliver
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [35] Preliminary product parameters from P11-1, a Phase 2, open-label trial of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer (mCRPC)
    Mulder, P.
    De Santis, M.
    Fizazi, K.
    Whitmore, J.
    Sheikh, N.
    McCoy, C.
    Stubbs, A.
    Powles, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
  • [36] Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naive, metastatic, castrate-resistant prostate cancer(CRPC)
    De Souza, P. L.
    Mellado, B.
    Pfister, C.
    Rosenthal, M.
    Castellano, D. E.
    Weber, D.
    Ferrara, S.
    Shaik, N.
    Tan, E.
    Patterson, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzal, Fatima
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Phillp M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)
    de Bono, J.
    Bracarda, S.
    Chi, K.
    Massard, C.
    Olmos Hidalgo, D.
    Sandhu, S.
    Sternberg, C. N.
    Gendreau, S.
    Xu, N.
    Baney, T.
    Maslyar, D.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Prognostic factors for patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy.
    Charnley, Natalie
    Birtle, Alison J.
    Swindell, Ric
    Parikh, Omi
    Wise, Marcus
    Kumar, Varadarajan
    Danwata, Falalu Dahiru
    Thompson, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
    Tsao, Che-Kai
    Sfakianos, John
    Liaw, Bobby
    Gimpel-Tetra, Kiev
    Kemeny, Margaret
    Bulone, Linda
    Shahin, Mohammad
    Oh, William Kyu
    Galsky, Matthew David
    ONCOLOGIST, 2016, 21 (12): : 1414 - +
12345